MedTrace Logo

A Study of Gemcitabine ± Erlotinib and DN-101 Versus Gemcitabine ± Erlotinib and Placebo in Patients With Advanced Pancreatic Cancer

NCT00536770 · Status: SUSPENDED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 132

Last updated 2007-11-06

No results posted yet for this study

Summary

The purpose of this study is to determine the safety and efficacy of an investigational study drug DN-101 (calcitriol) when given in combination with gemcitabine ± erlotinib in the treatment of pancreatic cancer.

Conditions

Interventions

DRUG

placebo + gemcitabine + erlotinib

DRUG

Placebo + gemcitabine

DRUG

calcitriol + gemcitabine

DRUG

calcitriol + gemcitabine + erlotinib

Sponsors & Collaborators

  • Schering-Plough

    collaborator INDUSTRY

  • Novacea

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-09-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00536770 on ClinicalTrials.gov